Sign inJoin waitlistJoin the waitlist

Ravi Madan

Physician · Clinical Center at the National Institutes of Health

Credentials: · ·

History

Clinical Center at the National Institutes of Health
Present

Hematology and Medical Oncology
2004–2007
Internal Medicine
2001–2004
Doctor of Medicine
1997–2001

Research

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Clinical Cancer Research · 2018 · 360 citations
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
The Lancet Oncology · 2012 · First of 13 authors · 271 citations
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
The Lancet Oncology · 2017 · 246 citations

James Gulley
144 papers
WD
William Dahut
70 papers
Fatima Karzai
55 papers
CH
Christopher Heery
34 papers · 6 as a fellow
Marijo Bilusic
33 papers · 1 as a fellow
PA
Philip Arlen
31 papers
William Figg
29 papers
Peter Choyke
27 papers
Ismail Turkbey
24 papers
Peter Pinto
21 papers
Julius Strauss
18 papers · 4 as a fellow
Deborah Citrin
14 papers

Grants

Evaluation of Novel Treatments in Biochemically Recurrent Prostate
National Cancer Institute · ZIA
Contact PI · $3.6M · Division of Basic Sciences - Nci
Evaluation of Immune-Based Combinations in Prostate Cancer
National Cancer Institute · ZIA
Contact PI · $3.1M · Division of Basic Sciences - Nci
Defining Roles for PSMA PET Imaging in Prostate Cancer
National Cancer Institute · ZIA
Contact PI · $1.4M · Division of Basic Sciences - Nci
Combination Therapies Involving Novel Cancer Vaccines
National Cancer Institute · ZIA
Contact PI · $418.4K · Division of Basic Sciences - Nci

Clinical trials

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
Principal investigator · Terminated · Phase 2
National Cancer Institute (NCI)
2019–2021
Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2018–2024
Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2017–2019
Prostvac in Patients With Biochemically Recurrent Prostate Cancer
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2015–2022